Trial Profile
A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2022
Price :
$35
*
At a glance
- Drugs Ganaxolone (Primary)
- Indications Status epilepticus
- Focus Therapeutic Use
- Sponsors Marinus Pharmaceuticals
- 23 Dec 2019 Status changed from recruiting to completed.
- 27 Sep 2018 Status changed from not yet recruiting to recruiting.
- 24 Nov 2017 New trial record